Drugs / Raluridine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00002338 | — | HIV infectious disease | Glaxo Wellcome | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Raluridine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002338 ↗ |
| Known as | 935U83 | “The Safety and Effectiveness of 935U83 in HIV-Infected Patients” NCT00002338 ↗ |
| Modality | Small molecule | — CHEMBL2106991 ↗ |
| Route | Oral | “multiple oral doses of 935U83 administered to patients with HIV infection” NCT00002338 ↗ |